Ask about this productRelated genes to: ANGPTL3 Blocking Peptide
- Gene:
- ANGPTL3 NIH gene
- Name:
- angiopoietin like 3
- Previous symbol:
- ANGPT5
- Synonyms:
- -
- Chromosome:
- 1p31.3
- Locus Type:
- gene with protein product
- Date approved:
- 2000-02-07
- Date modifiied:
- 2015-11-11
Related products to: ANGPTL3 Blocking Peptide
Related articles to: ANGPTL3 Blocking Peptide
- Patients with polycystic ovary syndrome face an increased risk of developing metabolic syndrome. Identifying biomarkers that can detect metabolic syndrome in polycystic ovary syndrome is essential, as it may enable physicians to implement preventive strategies aimed at reducing the risk of metabolic complications. The aim of this study was to assess angiopoietin-like protein-3 levels in polycystic ovary syndrome and to investigate the potential of angiopoietin-like protein-3 for discriminating metabolic syndrome in polycystic ovary syndrome. - Source: PubMed
Publication date: 2026/05/11
Karaca Özgenur AyvazOzgen GultenDogan OzlemDincgez BurcuOzgen Levent - Reducing plasma levels of low-density lipoprotein cholesterol (LDL-C) is the cornerstone in the prevention of coronary artery disease (CAD) but may also increase risk of type 2 diabetes (T2D). A comprehensive examination of the genetic evidence of T2D related side-effects of all current lipid-modifying drugs, including those in development, has not yet been performed. - Source: PubMed
Publication date: 2026/05/14
Chen ZekaiTriatin Rima DLuo LiSnieder HaroldSchmidt A FloriaanDitmarsch MarcKastelein John J PDullaart Robin P FKuivenhoven Jan AlbertThio Chris H L - Gene therapy has emerged as a promising and pivotal strategy for addressing numerous genetic disorders that currently lack effective therapeutic options. For many other presently incurable conditions, including the majority of inherited metabolic liver diseases, gene therapy offers a realistic and transformative treatment modality. This review highlights recent advancements in gene delivery vectors targeting the liver-specifically hepatocytes-with a focus on strategies involving gene supplementation and gene editing, as well as notable progress achieved through RNA-based therapeutic agents. Several early trials utilizing lipid nanoparticle (LNP)-based and recombinant adeno-associated virus (rAAV)-mediated approaches for gene supplementation and editing in liver diseases have yielded encouraging results. For example, rAAV-mediated FIX supplementation (2 × 10 genome copies/kg) achieves sustained therapeutic activity in a subset of HOPE-B trial participants with hemophilia B, and LNP-CRISPR editing of ANGPTL3 (0.5 mg/kg mRNA) produces marked reductions in LDL-C and triglycerides. However, several translational challenges have been identified, including unintended activation of the innate immune system and severe hepatotoxicity following high-dose vector administration. These concerns necessitate rigorous and ongoing safety monitoring. In this review, we summarize major advancements, current challenges, and future perspectives in the field of liver-directed gene therapy. Additionally, we highlight key limitations inherent to existing approaches and discuss potential strategies to overcome these barriers and improve therapeutic outcomes. - Source: PubMed
Publication date: 2026/05/11
Yan MengyaoXiang Qian - Coronary artery disease has a high degree of morbidity and mortality internationally, and after a cardiovascular event, patients require intensified management of modifiable risk factors, with optimal lipid control being an important cornerstone of secondary prevention. This is both a primary and secondary care responsibility. Familiarity with indications for and prescription of non-statin medications including injectables is vital for patient outcomes. Fewer than 30% of patients reach LDL-c targets with statins alone. This is a public health matter, and non-statin therapies all clinicians need to be aware of are oral therapies such as ezetimibe and bempedoic acid, and injectable therapies such as inclisiran and PCKS9 inhibitors. Icosapent ethyl is also available in those with high fasting triglycerides with specific LDL-c values. Understanding of when to refer to the lipid clinic enables patients to be managed appropriately in the correct setting. Future therapies under development include cholesterol ester transfer protein inhibitors, oral PCSK9 inhibitors, and gene editing therapy targeting ANGPTL3 and PCSK9. Lipid optimisation leads to significant MACE reduction, and familiarity with all available treatment options including non-statins and injectables will facilitate best primary and secondary care. - Source: PubMed
Publication date: 2026/05/08
Han JennieMasmanian EvaWang TimothyChua Tuan Peng - - Source: PubMed
Publication date: 2026/05/09
Ke JingXu YongsongZhu YingjunFeng XiaotongCao HaodiYang LongyanZhao Dong